Teva Pharmaceutical Industries Limited (TEVA) move down -1.81% this morning: TEVA Price downtrend Looks Real

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has a beta of 1.42. The stock’s Relative Strength Index (RSI) is 39.91, with weekly volatility at 2.69% and ATR at 0.50. The TEVA stock’s 52-week price range has touched low of $6.25 and a $13.56 high. Its shares traded lower over the last trading session, losing -1.81% on 02/22/21. The shares fell to a low of $10.8104 before closing at $10.84. Intraday shares traded counted 8.67 million, which was 7.21% higher than its 30-day average trading volume of 9.34M. TEVA’s previous close was $11.04 while the outstanding shares total 1.10B.

Investors have identified the Drug Manufacturers – Specialty & Generic company Teva Pharmaceutical Industries Limited as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $11.87 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Teva Pharmaceutical Industries Limited (TEVA) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TEVA, the company has in raw cash 2.18 billion on their books with 3.19 billion currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 13.01 billion total, with 13.16 billion as their total liabilities.

Having a look at the company’s valuation, the company is expected to record 2.63 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TEVA sounds very interesting.

Is the stock of TEVA attractive?

In related news, Exec. VP Chief Legal Officer, Stark David Matthew sold 3,926 shares of the company’s stock in a transaction that recorded on Feb 16. The sale was performed at an average price of 11.12, for a total value of 43,669. As the sale deal closes, the Executive VP, Global R&D, Fridriksdottir Hafrun now sold 2,098 shares of the company’s stock, valued at 23,336. Also, Executive VP Global Operations, Drape Eric sold 2,079 shares of the company’s stock in a deal that was recorded on Feb 16. The shares were price at an average price of 11.13 per share, with a total market value of 23,135. Following this completion of acquisition, the Exec. VP Chief Legal Officer, Stark David Matthew now holds 65,312 shares of the company’s stock, valued at 829,103. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.02%.

3 out of 23 analysts covering the stock have rated it a Buy, while 17 have maintained a Hold recommendation on Teva Pharmaceutical Industries Limited. 1 analysts has assigned a Sell rating on the TEVA stock. The 12-month mean consensus price target for the company’s shares has been set at $12.35.


Please enter your comment!
Please enter your name here